Tvardi Therapeutics to Participate in Upcoming Investor Conferences
Details are as follows:
Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways
Format: Fireside Chat
Date: Tuesday, May 27, 2025
Time: 11:30 AM ET
Jefferies Global Healthcare Conference
Format: Corporate Presentation and Investor Meetings
Date: Wednesday, June 4, 2025
Time: 11:40 AM ET
The webcast of the Jefferies presentation will be accessible on the Tvardi Investors’ website. A replay of the webcast will be available for approximately 60 days following the conference.
About Tvardi Therapeutics
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in fibrosis-driven diseases with high unmet need: idiopathic pulmonary fibrosis (NCT05671835) and hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520914596/en/
For Tvardi:
Tvardi Investor Relations
ir@tvardi.com
PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com
Source: Tvardi Therapeutics, Inc.
